Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
|Slideshows|January 22, 2020
8 Strategies for Managing BPSD
Author(s)Natalie Timoshin
Recommendations for the use of antipsychotics for the management of behavioral and psychological symptoms of dementia.
Advertisement
Advertisement
Related to this article
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
5